Dasatinib
Dasatinib is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Dasatinib; Generic name: DASATINIB; Manufacturer: Prasco Laboratories.
| Brand name | Dasatinib |
|---|---|
| Generic name | DASATINIB |
| Manufacturer | Prasco Laboratories |
| Used for | 1 INDICATIONS AND USAGE Dasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase. newly diagnosed Ph+ ALL in combination with chemotherapy. Dasatinib tablets are a kinase inhibitor indicated for the t |
| Dosage | 2 DOSAGE AND ADMINISTRATION Chronic phase CML in adults: 100 mg once daily. (2) Accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL in adults: 140 mg once daily. (2) Chronic phase CML and ALL in pediatrics: starting dose based on body weight. (2) Administer orally, with or without a meal. Do not crush, cut, or chew tablets. (2) 2.1 Dosage of Dasatinib Tablets in Adult Patients The recommended starting dosage of Dasatinib tablets for chronic phase CML in adults is 100 mg admini |
| Active ingredient(s) | DASATINIB |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1931e73f-918c-4d69-9543-de9643513d05 |